M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition-Reference-Cited by-同舟云学术

M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition

Published:2018-03-14 Issue:8 Volume:43 Page:1763-1771
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Moran Sean P.,Dickerson Jonathan W.,Cho Hyekyung P.,Xiang Zixiu^ORCID,Maksymetz James,Remke Daniel H.,Lv Xiaohui,Doyle Catherine A.,Rajan Deepa H.,Niswender Colleen M.,Engers Darren W.,Lindsley Craig W.,Rook Jerri M.,Conn P. Jeffrey

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/s41386-018-0033-9.pdf

Reference46 articles.

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403.

2. Sarter M, Lustig C, Taylor SF. Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology. 2012;62:1544–53.

3. Dean B, Hopper S, Conn PJ, Scarr E. Changes in BQCA allosteric modulation of [(3)H]NMS binding to human cortex within schizophrenia and by divalent cations. Neuropsychopharmacology. 2016;41:1620–8.

4. Scarr E, Udawela M, Thomas EA, Dean B.Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor. Mol Psychiatry. 2016;23:295–303.

5. Foster DJ, Conn PJ. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron. 2017;94:431–46.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of VU6007496: Challenges in the Development of an M₁ Positive Allosteric Modulator Backup Candidate;ACS Chemical Neuroscience;2024-08-28

2. A golden age of muscarinic acetylcholine receptor modulation in neurological diseases;Nature Reviews Drug Discovery;2024-08-14

3. Anticholinergic drugs for parkinsonism and other movement disorders;Journal of Neural Transmission;2024-06-21

4. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M₄ Muscarinic Acetylcholine Receptor;Journal of Medicinal Chemistry;2024-06-18

5. Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials;Brain Sciences;2024-01-24